Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958525 | 0.81 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL20047604 | 0.81 | CYP1A2 (0.46) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL862233 | 0.79 | CYP1A2 (0.60) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL31186677 | 0.79 | CYP1A2 (0.60) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL10259445 | 0.76 | CYP1A2 (0.68) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL13676602 | 0.74 | ALDH1A1 (0.50) | CYP1A2KDM4EPOLBCASP6MEN1 | |
| SCHEMBL9217980 | 0.74 | CYP1A2 (0.65) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL13335949 | 0.73 | POLB (0.46) | CYP1A2KDM4ELMNAPOLBMEN1 | |
| SCHEMBL244724 | 0.72 | CYP1A2 (0.52) | CYP1A2KDM4ELMNAPOLBCASP6 | |
| SCHEMBL12025134 | 0.72 | CYP1A2 (0.57) | CYP1A2KDM4ELMNAPOLBCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | CYP1A2 424/4885KDM4E 3365/4885LMNA 1185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.